These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32372486)

  • 1. Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial.
    Bolland MJ; House ME; Horne AM; Pinel V; Gamble GD; Grey A; Reid IR
    J Bone Miner Res; 2020 Jun; 35(6):1040-1047. PubMed ID: 32372486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension.
    Koh JM; Chung DJ; Chung YS; Kang MI; Kim IJ; Min YK; Oh HJ; Park IH; Lee YS; Kravitz B; Waterhouse B; Nino A; Fitzpatrick LA
    Yonsei Med J; 2016 Jul; 57(4):905-14. PubMed ID: 27189284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial.
    Bucur RC; Reid LS; Hamilton CJ; Cummings SR; Jamal SA
    Trials; 2013 Sep; 14():284. PubMed ID: 24010992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
    Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
    J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
    Matsumoto T; Sone T; Yamashita A; Inoue T
    J Bone Miner Metab; 2023 Nov; 41(6):807-816. PubMed ID: 37505256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial.
    Benjawan S; Nimitphong H; Tragulpiankit P; Musigavong O; Prathanturarug S; Pathomwichaiwat T
    Phytomedicine; 2022 Jul; 101():154115. PubMed ID: 35523116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    J Bone Miner Res; 2022 Jan; 37(1):3-11. PubMed ID: 34585780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.